Abstract
Protein kinases are enzymes that are important for controlling cellular growth and invasion1, and their malfunction is implicated in the development of some tumours. We analysed human colorectal cancers for genetic mutations in 340 serine/threonine kinases and found mutations in eight genes, including in three members of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway. The discovery of this mutational activation of a key cell-signalling pathway may provide new targets for therapeutic intervention.
Similar content being viewed by others
Main
Although genetic alterations in tyrosine kinases have previously been firmly implicated in tumorigenesis, only a few serine/threonine kinases (STKs) are known to be mutated in human cancers1,2,3,4. We selected 340 genes encoding STKs from the human genome5 and analysed them for mutations in tumours from colorectal cancer patients (for details, see supplementary information). As the catalytic domains of these genes are most likely to harbour mutations that activate the gene product1, we focused on stretches (exons) containing the kinase domains.
These exons were amplified by using polymerase chain reaction (PCR) on template DNA derived from 24 colorectal cancers and were then sequenced directly. Any observed changes were evaluated against DNA from patient-matched normal tissue to identify somatic (tumour-specific) mutations. The entire coding regions of those genes found to contain mutations were then further evaluated in a larger panel of 180 colorectal tumours. A total of 23 changes, including 20 non-synonymous point mutations, one insertion and one splice-site alteration, were identified (see supplementary information).
The gene mutations affected eight different proteins: six were in mitogen-activated protein-kinase kinase-4 (MKK4/JNKK1), six in myosin light-chain kinase-2 (MYLK2), three in phosphoinositide-dependent protein kinase-1 (PDK1, of which two mutations affect the same residue in the kinase domain), two in p21-activated kinase 4 (PAK4), two in v-akt murine thymoma viral oncogene homologue-2 kinase (AKT2), and two in MAP/microtubule affinity-regulating kinase-3 (MARK3); there was one alteration in cell-division cycle-7 kinase (CDC7) and another in a hypothetical casein kinase (PDIK1L). Eighteen of the 23 somatic mutations occurred at evolutionarily conserved residues.
MKK4/JNKK1 is altered in a variety of tumour types6, but no mutations in any of the other genes have previously been found in colorectal cancers. Three of the altered genes, PDK1, AKT2 and PAK4, encode proteins involved in the PI(3)K signalling pathway7,8 (Fig. 1), and two of these (AKT2 and PAK4) are overexpressed in human cancers1.
We tested whether any of the three kinases could have been altered by amplification, another mechanism for kinase activation. Quantitative PCR analysis of 146 colorectal tumours showed co-amplification of AKT2 and PAK4 on chromosome 19q13.2 in two samples, which we confirmed by digital karyotyping9 and fluorescent in situ hybridization (see supplementary information).
We also evaluated other non-STK members of the PI(3)K pathway in the same 146 samples (Fig. 1, and see supplementary information)7 and found one mutation in the insulin-related receptor INSRR, one in the v-Erb-B erythroblastic leukaemia viral oncogene homologue ERBB4, seven in the phosphatase-and-tensin homologue PTEN, and three cases of amplification of the insulin-receptor substrate IRS2 (see supplementary information). When these alterations are compared with those previously discovered in the phosphoinositide-3-kinase p110α catalytic subunit PIK3CA (ref. 10), their distribution is striking: all but two of the 58 alterations were in different tumours (P=0.02, ξ2 test), indicating that the mutated genes probably have equivalent tumorigenic effects and are operating through the same pathway.
Overall, nearly 40% of colorectal tumours had alterations in one of eight PI(3)K-pathway genes: as most of these encode protein kinases, they could serve as sites for therapeutic intervention. Also, targeting the downstream genes PDK1 or AKT2 could be effective against the much larger fraction of tumours that contain mutations in PIK3CA or PTEN.
References
Blume-Jensen, P. & Hunter, T. Nature 411, 355–365 (2001).
Bardelli, A. et al. Science 300, 949 (2003).
Davies, H. et al. Nature 417, 949–954 (2002).
Futreal, P. A. et al. Nature Rev. Cancer 4, 177–183 (2004).
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. Science 298, 1912–1934 (2002).
Teng, D. H. et al. Cancer Res. 57, 4177–4182 (1997).
Vivanco, I. & Sawyers, C. L. Nature Rev. Cancer 2, 489–501 (2002).
Wells, C. M., Abo, A. & Ridley, A. J. J. Cell Sci. 115, 3947–3956 (2002).
Wang, T. L. et al. Proc. Natl Acad. Sci. USA 99, 16156–16161 (2002).
Samuels, Y. et al. Science 304, 554 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
K.W.K and V.E.V. received research funding from Genzyme Molecular Oncology (Genzyme), Boston, Massachusetts. K.W.K. and V.E.V. are consultants to Genzyme. The Johns Hopkins University, B.V., K.W.K. and V.E.V. own Genzyme stock, which is subject to certain restrictions within university policy. The terms of these arrangements are being managed by the university in accordance with its conflict-of-interest policies.
Supplementary information
Supplementary Methods
(DOC 44 kb)
Supplementary Table 1
Serine/threonine kinome genes analysed (PDF 27 kb)
Supplementary Table 2
Mutations in the serine/threonine kinome in colorectal cancer (PDF 10 kb)
Supplementary Table 3
PI(3)K pathway genes analyzed (PDF 18 kb)
Supplementary Table 4
Mutations of PI(3)K pathway genes in colorectal cancer (PDF 10 kb)
Supplementary Figure 1
Amplification of AKT2 / PAK4 in colorectal cancer (PDF 32 kb)
Rights and permissions
About this article
Cite this article
Parsons, D., Wang, TL., Samuels, Y. et al. Mutations in a signalling pathway. Nature 436, 792 (2005). https://doi.org/10.1038/436792a
Published:
Issue Date:
DOI: https://doi.org/10.1038/436792a
This article is cited by
-
A novel nomogram based on cell cycle-related genes for predicting overall survival in early-onset colorectal cancer
BMC Cancer (2023)
-
Comprehensive analysis of the prognostic implications and functional exploration of PAK gene family in human cancer
Cancer Cell International (2022)
-
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer
Molecular Cancer (2022)
-
Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations
Scientific Reports (2020)
-
LINC01088 inhibits tumorigenesis of ovarian epithelial cells by targeting miR-24-1-5p
Scientific Reports (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.